Revolutionizing Clinical Trials with AI
Digital Twin technology can help overcome challenges of traditional methods for clinical trials, but realizing its full potential will require close collaboration between industry and regulators.
By
Luba Greenwood, Mary Scarpulla, Monika Pichler, Aseem Mahajan, and Colleen Carroll
August 7, 2024
The healthcare industry is on the cusp of transformation thanks to recent advances in AI. One of the most promising advances is the use of digital twins – digital replicas of cells, organs, or even entire patients. These models allow researchers to predict clinical outcomes in simulated environments, reducing the time and cost of drug development significantly. In this new paper by Keystone's Mary Scarpulla, Aseem Mahajan, and Monika Pichler, in collaboration with Keystone expert Luba Greenwood and Keystone Alumna Colleen Carroll, we explore:
- The technological advancements that have enabled the advent of advanced analytical tools in the healthcare space, including the promising digital twin technology
- What digital twin technology is, and how it can be leveraged by the healthcare industry
- The global regulatory landscape and how it could impact the adoption of this technology
- Directional insights on how regulatory bodies can facilitate adoption while ensuring patient safety
Click here to download the paper. A version of this paper was also published in Law360. Law360 users can read it here.
